Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer
- 19 February 2020
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1867 (6) , 118679
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 104 references indexed in Scilit:
- Aspirin Use, TumorPIK3CAMutation, and Colorectal-Cancer SurvivalNew England Journal of Medicine, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitorsProceedings of the National Academy of Sciences, 2011
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and ActivityCancer Cell, 2011
- Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domainsProceedings of the National Academy of Sciences, 2010
- Protein Tyrosine Kinase 6 Directly Phosphorylates AKT and Promotes AKT Activation in Response to Epidermal Growth FactorMolecular and Cellular Biology, 2010
- Specific Roles of the p110α Isoform of Phosphatidylinsositol 3-Kinase in Hepatic Insulin Signaling and Metabolic RegulationCell Metabolism, 2010
- Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastomaNeuro-Oncology, 2010
- A frequent kinase domain mutation that changes the interaction between PI3Kα and the membraneProceedings of the National Academy of Sciences, 2009
- Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapyLeukemia, 2003